
US President Donald Trump has nominated Heidi Overton, deputy director of the White House Domestic Policy Council, as the next commissioner of the Food and Drug Administration (FDA), announcing the choice in a social media post on Wednesday.
Dr Overton is a physician who has worked on several of the administration's second-term health initiatives, including drug pricing agreements with manufacturers and an effort to accelerate development of psychedelic treatments. She trained in general surgery at Johns Hopkins and was a White House fellow during President Trump's first term.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
| Headless Content Management with Blaze